通心络胶囊对经皮冠状动脉介入治疗术后患者心功能改善及心肌酶谱表达的影响

Effect of Tongxinluo capsule on improvement of cardiac function and expression of myocardial enzyme spectrum in patients with coronary heart disease after percutaneous coronary intervention

目的探讨通心络胶囊对经皮冠状动脉介入治疗(PCI)术后患者心功能改善及心肌酶谱表达的影响。方法选择2018年4月至2020年4月在河北省香河县人民医院接受PCI的冠心病患者100例,按随机数字表法分为观察组和对照组各50例,对照组术后给予常规治疗,观察组术后给予以常规治疗联合通心络胶囊口服,两组患者均治疗3个月。观察治疗后两组患者临床症状缓解情况;比较两组治疗前后心功能[左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)、左心室射血分数(LVEF)]改善及心肌酶[丙氨酸氨基转移酶(AST)、肌酸激酶(CK)、肌酸激酶同工酶-MB(CK-MB)、乳酸脱氢酶(LDH)、肌钙蛋白T(TnT)]水平变化。结果治疗3个月后,观察组总有效率高于对照组[92.0%(46/50比76.0%(38/50)],差异有统计学意义(χ^(2) = 4.76,P<0.05)。治疗后两组LVEDV及LVESV降低,LVEF升高,并且观察组治疗后LVEDV及LVESV低于对照组[(153.39 ± 8.35) ml/m^(2)比(155.57 ± 9.32) ml/m^(2)、(103.49 ± 9.25) ml/m^(2)比(109.65 ± 10.46) ml/m^(2)],LVEF高于对照组[(58.14 ± 7.41)%比(54.59 ± 6.92)%],差异均有统计学意义(P<0.05)。治疗后两组AST、CK、CK-MB、LDH、TnT均明显降低,并且观察组上述指标低于对照组[(38.14 ± 7.28) U/L比(45.04 ± 8.12) U/L、(637.15 ± 75.25) U/L比(756.24 ± 85.24) U/L、(553.28 ± 53.14) U/L比 (632.17 ± 62.81) U/L、(162.43 ± 15.41) U/L比(181.74 ± 19.25) U/L、(0.32 ± 0.15) μg/L比 (0.39 ± 0.11) μg/L],差异均有统计学意义(P<0.05)。结论冠心病PCI术后患者应用通心络胶囊可有效缓解临床症状,改善心功能,调节机体酶活性。

Objective To investigate the effects of Tongxinluo capsule on the improvement of cardiac function and the expression of myocardial enzyme spectrum in patients with coronary heart disease after percutaneous coronary intervention(PCI).Methods One hundred patients with coronary heart disease after PCI who received treatment in Hebei Xianghe County People′s Hospitalfrom April 2018 to April 2020 were enrolled and randomly divided into the observation group and the control group.The control group was given conventional treatment,while the observation group was treated with Tongxinluo capsule on the basis of the control group.Patients in both groups were treated for 3 months.The normal clinical remission after treatment was observed in the two groups.The improvement of cardiac function index left ventricular end-diastolic volume(LVEDV),left ventricular end-systolic volume(LVESV),left ventricular ejection fraction(LVEF)and myocardial enzyme index aspartate aminotransferase(AST),creatine kinase(CK),creatine kinase isoenzyme-MB(CK-MB),lactate dehydrogenase(LDH),troponin T(TnT)were compared between the two groups before and after the treatment.Results After treated for 3 months,the total effective rate in the observation group was higher than that in the control group:92.0%(46/50)vs.76.0%(38/50),the difference was statistically significant(χ^(2)=4.76,P<0.05).After treated for 3 months,the levels of LVEDV and LVESV in two groups were decreased,and the level of LVEF in two groups was increased,and the levels of LVEDV and LVESV in the observation group were lower than those in the control group:(153.39±8.35)ml/m^(2) vs.(155.57±9.32)ml/m^(2),(103.49±9.25)ml/m^(2) vs.(109.65±10.46)ml/m^(2);the levels of LVEF in the observation group was higher than that in the control group:(58.14±7.41)%vs.(54.59±6.92)%,the differences were statistically significant(P<0.05).After treated for 3 months,the levels of AST,CK,CK-MB,LDH,TnT in two groups were decreased,and the levels of above index in the observation group were lower than those in the control group:(38.14±7.28)U/L vs.(45.04±8.12)U/L,(637.15±75.25)U/L vs.(756.24±85.24)U/L,(553.28±53.14)U/L vs.(632.17±62.81)U/L,(162.43±15.41)U/L vs.(181.74±19.25)U/L,(0.32±0.15)μg/L vs.(0.39±0.11)μg/L,the differences were statistically significant(P<0.05).Conclusions The application of Tongxinluo capsule in patients with coronary heart disease after PCI can effectively alleviate clinical symptoms,improve cardiac function,and regulate the enzyme activity of the body.